日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

How does pulmonary function impact QoL in patients with locally advanced NSCLC treated with chemoradiotherapy and durvalumab?

肺功能如何影响接受放化疗和度伐利尤单抗治疗的局部晚期非小细胞肺癌患者的生活质量？

期刊:Acta Oncologica
影响因子:2.2
doi:10.2340/1651-226X.2026.45040
Sommervoll, Frigg Å; Horndalsveen, Henrik; Sommervoll, Dag Einar; Koivonen, Jussi; Halvorsen, Tarje Onsøien; Grønberg, Bjørn Henning; Aanerud, Marianne; Cicenas, Saulius; Helbekkmo, Nina; Ahvonen, Jarkko; Silvoniemi, Maria; Barrera, Gina; Bjaanæs, Maria M; Haakensen, Vilde; Öjlert, Åsa; Oselin, Kersti; Helland, Åslaug; Madebo, Tesfaye
肺癌
细胞生物学
肿瘤
肿瘤免疫
发表日期：2026
文献求助 收藏

Blood-based tumor mutational burden as a biomarker in unresectable non-small cell lung cancer treated with chemoradiotherapy and durvalumab

血液肿瘤突变负荷作为不可切除的非小细胞肺癌患者接受放化疗和度伐利尤单抗治疗的生物标志物

期刊:Frontiers in Oncology
影响因子:3.3
doi:10.3389/fonc.2025.1681420
Horndalsveen, Henrik; Haakensen, Vilde Drageset; Madebo, Tesfaye; Grønberg, Bjørn Henning; Halvorsen, Tarje Onsøien; Koivunen, Jussi; Oselin, Kersti; Cicenas, Saulius; Helbekkmo, Nina; Aanerud, Marianne; Ahvonen, Jarkko; Silvoniemi, Maria; Bjaanæs, Maria Moksnes; Farooqi, Saima; Nebdal, Daniel; Dalsgaard, Astrid Marie; Danielsen, Britina Kjuul; Børve, Mari; Dalen, Tonje Sofie; Öjlert, Åsa Kristina; Helland, Åslaug
肺癌
细胞生物学
肿瘤
肿瘤免疫
发表日期：2025
文献求助 收藏

Too much or too little? The trajectory of systemic anti-cancer treatment throughout the last year of life of lung cancer patients in Norway

治疗过量还是不足？挪威肺癌患者生命最后一年全身抗癌治疗的轨迹

期刊:
影响因子:
doi:10.1038/s44276-025-00183-w
Solberg, Steinar; Slørdahl, Kathinka Schmidt; Aanerud, Marianne; Brustugun, Odd Terje; Grønberg, Bjørn Henning; Helbekkmo, Nina; Helland, Åslaug; Nilssen, Yngvar
肺癌
肿瘤
肿瘤免疫
发表日期：2025
文献求助 收藏

Atezolizumab and stereotactic body radiotherapy in patients with advanced non-small cell lung cancer: safety, clinical activity and ctDNA responses-the ComIT-1 trial

阿特珠单抗联合立体定向放射治疗晚期非小细胞肺癌患者：安全性、临床活性和ctDNA反应——ComIT-1试验

期刊:Molecular Oncology
影响因子:4.5
doi:10.1002/1878-0261.13330
Horndalsveen, Henrik; Alver, Tine Norman; Dalsgaard, Astrid Marie; Rogg, Lotte Victoria; Helbekkmo, Nina; Grønberg, Bjørn Henning; Halvorsen, Tarje Onsøien; Ramberg, Christina; Haakensen, Vilde Drageset; Öjlert, Åsa Kristina; Bjaanaes, Maria Moksnes; Helland, Åslaug
肺癌
细胞生物学
肿瘤
肿瘤免疫
发表日期：2023
文献求助 收藏

Pembrolizumab as second-line therapy in non-small cell lung cancer in northern Norway: budget impact and expected gain-a model-based analysis

在挪威北部，帕博利珠单抗作为非小细胞肺癌二线治疗：预算影响和预期收益——基于模型的分析

期刊:ESMO Open
影响因子:8.3
doi:10.1136/esmoopen-2017-000222
Norum, Jan; Antonsen, Margareth Aarag; Tollåli, Terje; Al-Shibli, Khalid; Andersen, Gry; Svanqvist, Kristin Helene; Helbekkmo, Nina
肺癌
细胞生物学
肿瘤
肿瘤免疫
发表日期：2017
文献求助 收藏

Poor prognosis patients with inoperable locally advanced NSCLC and large tumors benefit from palliative chemoradiotherapy: a subset analysis from a randomized clinical phase III trial

预后不良的局部晚期非小细胞肺癌（NSCLC）患者，尤其是肿瘤较大且无法手术的患者，可从姑息性放化疗中获益：一项随机III期临床试验的亚组分析

期刊:Journal of Thoracic Oncology
影响因子:20.8
doi:10.1097/JTO.0000000000000184
Strøm, Hans H; Bremnes, Roy M; Sundstrøm, Stein H; Helbekkmo, Nina; Aasebø, Ulf
肺癌
肿瘤
肿瘤免疫
CLC
细胞生物学
发表日期：2014
文献求助 收藏

Concurrent palliative chemoradiation leads to survival and quality of life benefits in poor prognosis stage III non-small-cell lung cancer: a randomised trial by the Norwegian Lung Cancer Study Group

同步姑息性放化疗可提高预后不良的III期非小细胞肺癌患者的生存率和生活质量：挪威肺癌研究组的一项随机试验

期刊:British Journal of Cancer
影响因子:6.8
doi:10.1038/bjc.2013.466
Strøm, H H; Bremnes, R M; Sundstrøm, S H; Helbekkmo, N; Fløtten, O; Aasebø, U
肺癌
细胞生物学
肿瘤
肿瘤免疫
发表日期：2013
文献求助 收藏